Edgar Filing: LANNETT CO INC - Form 8-K

LANNETT CO INC Form 8-K June 25, 2004

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Date of Report (Date of earliest event reported): June 23, 2004

LANNETT COMPANY, INC. (Exact Name of Registrant as Specified in Its Charter)

Delaware	0-9036	23-0787-699
State or other Jurisdiction	Commission	I.R.S. Employer
of Incorporation or Organization	File Number	Identification No.

Registrant's telephone number, including area code: (215) 333-9000

ITEM 5: OTHER EVENTS AND REGULATION FD DISCLOSURE

On June 23, 2004, registrant announced that the supplier of its levothyroxine sodium tablet product, Jerome Stevens Pharmaceutical, Inc. (JSP), had received a letter from the United States Food and Drug Administration (FDA) approving JSP's supplemental application for bioequivalence, commonly referred to as an AB rating, to Levoxyl(R), which is marketed by Monarch Pharmaceutical, a division of King Pharmaceuticals, Inc. Lannett issued a press release, a copy of which is included as Exhibit 99.1 hereto. This information shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, and is not incorporated by reference into any filing of the Company, whether made before or after the date of this report, regardless of any general incorporation language in the filing.

ITEM 7: FINANCIAL STATEMENTS AND EXHIBITS

- (C) Exhibits
- 99.1 June 23, 2004 Press Release

Edgar Filing: LANNETT CO INC - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

LANNETT COMPANY, INC

By: /s/ Larry Dalesandro Chief Financial Officer

Date: June 24, 2004

EXHIBIT INDEX

Exhibit: Description:

99.1 June 24, 2004 Press Release